title: Androgen deprivation therapy and definitive radiotherapy for prostate cancer.
abstract: Adjuvant androgen deprivation therapy (ADT) improves outcomes of patients receiving definitive radiotherapy (RT) for local-regionally advanced prostate cancer. However, patients in most randomized trials had more advanced disease than observed in many practices and were treated with suboptimal RT doses. Although data are conflicting, long-term ADT likely has adverse side-effects in patients with comorbidities. We recommend 6 months of ADT monotherapy with gonadotropin-releasing hormone agonist and RT for patients with high-risk prostate cancer (≥T2c, Gleason Score 8 to 10, and/or prostate-specific antigen ≥20 ng/mL) with minimal or no comorbidities. Adjuvant ADT for unfavorable intermediate-risk patients with a Gleason Score of 4+3=7 is also reasonable.
authors.affiliation: *Department of Radiation Oncology at the University of Florida College of Medicine, Gainesville †University of Florida Proton Therapy Institute, Jacksonville, FL.
authors.forename: William M
authors.initials: WM
authors.lastname: Mendenhall
authors.forename: Randal H
authors.initials: RH
authors.lastname: Henderson
authors.forename: Bradford S
authors.initials: BS
authors.lastname: Hoppe
authors.forename: Romaine Charles
authors.initials: RC
authors.lastname: Nichols
authors.forename: Nancy P
authors.initials: NP
authors.lastname: Mendenhall
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D001918:Brachytherapy; D059248:Chemoradiotherapy; D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000628:therapy*
chemical_list: D000726:Androgen Antagonists